MannKind Co. (NASDAQ:MNKD) Insider Sells $156,500.00 in Stock

MannKind Co. (NASDAQ:MNKD) insider Stuart A. Tross sold 25,000 shares of the firm’s stock in a transaction on Tuesday, September 3rd. The stock was sold at an average price of $6.26, for a total value of $156,500.00. Following the transaction, the insider now directly owns 1,022,191 shares of the company’s stock, valued at $6,398,915.66. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

MannKind Trading Down 1.7 %

MNKD stock opened at $5.93 on Friday. The firm has a market cap of $1.61 billion, a PE ratio of 197.67 and a beta of 1.32. The stock has a 50-day moving average price of $5.54 and a 200-day moving average price of $4.87. MannKind Co. has a 1-year low of $3.17 and a 1-year high of $6.44.

MannKind (NASDAQ:MNKD) last issued its quarterly earnings results on Wednesday, August 7th. The biopharmaceutical company reported $0.05 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.01 by $0.04. The firm had revenue of $72.39 million for the quarter, compared to analyst estimates of $64.81 million. MannKind had a negative return on equity of 11.97% and a net margin of 4.73%. The company’s revenue was up 48.9% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.02) earnings per share. On average, analysts forecast that MannKind Co. will post 0.11 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the stock. Meeder Asset Management Inc. acquired a new position in shares of MannKind during the second quarter valued at about $55,000. 9258 Wealth Management LLC acquired a new position in MannKind during the 1st quarter worth approximately $51,000. Brookstone Capital Management bought a new position in MannKind in the second quarter worth approximately $61,000. Renaissance Technologies LLC acquired a new stake in MannKind in the second quarter valued at approximately $67,000. Finally, EntryPoint Capital LLC increased its holdings in shares of MannKind by 60.9% during the first quarter. EntryPoint Capital LLC now owns 23,809 shares of the biopharmaceutical company’s stock valued at $108,000 after acquiring an additional 9,008 shares in the last quarter. 49.55% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on MNKD shares. Rodman & Renshaw began coverage on MannKind in a research note on Thursday, June 13th. They issued a “buy” rating and a $8.00 price target for the company. Oppenheimer raised their price target on shares of MannKind from $10.00 to $12.00 and gave the stock an “outperform” rating in a report on Wednesday, August 28th. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the stock. According to data from MarketBeat.com, MannKind currently has a consensus rating of “Moderate Buy” and a consensus target price of $8.80.

MannKind Company Profile

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults.